Galanin receptor 3 - a potential target for acute pancreatitis therapy

Savio Barreto, Maryam Bazargan, Maria Zotti, Damian Hussey, Olga Sukocheva, Galhenage Peiris, Mary Leong, Damien Keating, Ann Schloithe, Colin Carati, C Smith, James Toouli, Gino Saccone

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Background Galanin participates in the pathogenesis of acute pancreatitis (AP). The galanin receptor (GALR) sub-types involved, however, are unclear. We aimed to determine GALRs messenger RNA (mRNA) expression in mouse pancreas, describe their localization, and ascertain if GALR2 and GALR3 are involved in AP. Methods Galanin receptor expression in murine whole pancreas, acinar, and islet cells was quantified by polymerase chain reaction amplification of reverse-transcribed RNA for mRNA, Western blot analysis for protein and in situ hybridization for GALR localization. Isolated acinar cells were used to determine galanin's effect on amylase secretion. Acute pancreatitis was induced in mice by caerulein injections. Mice, with and without AP, were treated with the highly selective GALR2 antagonist M871, or the specific GALR3 antagonist SNAP-37889. Indices of AP were measured at 12h. Key Results Murine pancreas expresses mRNA for GALRs. In islets the expression of all GALR are comparable, whereas in acinar cells GALR3 is predominantly expressed. Western blot analysis confirmed that the GALR proteins are expressed by acinar cells. In situ hybridization analysis confirmed that GALR3 mRNA is present in islet and acinar cells, while mRNA for GALR1 and 2 is confined to islets. Galanin did not influence basal and caerulein-stimulated amylase release from acinar cells. M871 treatment reduced some, whereas SNAP-37889 treatment reduced all indices of AP (by 40-80%). Conclusions & Inferences Galanin receptor mRNA and protein are expressed in mouse pancreas, with GALR3 mRNA predominating. GALR3 antagonism reduced the severity of AP whereas GALR2 antagonism was less effective. GALR3 is a potential target for treatment of AP.

    Original languageEnglish
    Pages (from-to)e141-e151
    Number of pages11
    JournalNeurogastroenterology and Motility
    Volume23
    Issue number3
    DOIs
    Publication statusPublished - 2011

    Fingerprint Dive into the research topics of 'Galanin receptor 3 - a potential target for acute pancreatitis therapy'. Together they form a unique fingerprint.

  • Cite this

    Barreto, S., Bazargan, M., Zotti, M., Hussey, D., Sukocheva, O., Peiris, G., Leong, M., Keating, D., Schloithe, A., Carati, C., Smith, C., Toouli, J., & Saccone, G. (2011). Galanin receptor 3 - a potential target for acute pancreatitis therapy. Neurogastroenterology and Motility, 23(3), e141-e151. https://doi.org/10.1111/j.1365-2982.2010.01662.x